Informace o publikaci

Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference

Autoři

BALIAKAS Panagiotis PUIGGROS Anna XOCHELLI Aliki SUTTON Lesley-Ann NGUYEN-KHAC Florence GARDINER Anne PLEVOVÁ Karla MINGA Eva HADZIDIMITRIOU Anastasia WALEWSKA Renata MCCARTHY Helen ORTEGA Margarita COLLADO Rosa GONZALEZ Teresa GRANADA Isabel LUNO Elisa KOTAŠKOVÁ Jana MOYSIADIS Theodoros DAVIS Zadie STAVROYIANNI Niki ANAGNOSTOPOULOS Achilles STREFFORD Jonathan C. POSPÍŠILOVÁ Šárka DAVI Frederic ATHANASIADOU Anastasia ROSENQUIST Richard OSCIER David ESPINET Blanca STAMATOPOULOS Kostas

Rok publikování 2016
Druh Článek v odborném periodiku
Časopis / Zdroj Haematologica
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
www https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004477/pdf/101e299.pdf
Doi http://dx.doi.org/10.3324/haematol.2015.140202
Obor Onkologie a hematologie
Klíčová slova RBC; cord blood; bio-engineered; native; metabolic profile
Popis Recurrent cytogenetic abnormalities in chronic lym- phocytic leukemia (CLL), namely deletions of chromo- somes 11q, 13q, 17p and trisomy 12 (+12), define sub- groups of patients with different clinical behavior and response to treatment. 1 We and others previously report- ed a minor proportion of CLL cases with co-existing tri- somies of chromosomes 12 and 19 who share specific clinico-biological characteristics. 2-4 However, since the cohort was small, no definitive conclusions could be drawn. Here, we analyzed a large, multi-institutional series. We confirm and significantly extend previous observations through the identification of subgroups of +12 CLL cases harboring particular concurrent trisomies demonstrating distinctive clinico-biological profiles. We analyzed an unselected cohort of 4486 CLL patients with available classic cytogenetic (n=4285) or high-density 250K single nucleotide polymorphism (SNP)-array (n=201) data. We identified 712 cases (16% of the cohort) carrying +12. 5 Median time from diagnosis to cytogenet- ic/SNP analysis was 1.5 months (range 0-194); the major- ity of cases included in survival analysis were untreated prior to testing (94%). The study was approved by the local Ethics Review Committees. Details of the study cohort and the methodologies used are provided in the Online Supplementary Appendix.
Související projekty: